PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
The objective of GCMC is well aligned to WHO’s call to action and India’s National Biotechnology Development Strategy
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
We are achieving the target of developed India by making our young children healthy today
Project achieves 30% reduction in hospital acquired infections and 24% reduction in the incidence of multi-drug resistant organisms
The project aims at screening the general health condition of the students enrolled in classes 6th to 12th.
Subscribe To Our Newsletter & Stay Updated